Bausch Health (MEX:BHCN) Moat Score: 5/10 (As of Jun. 25, 2026)


MEX:BHCN Bausch Health Companies Inc MEX:BHCN
48 GF Score
Price MXN85.44
GF Value MXN188.23
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Bausch Health Moat Score?

Bausch Health MEX:BHCN 48 Moat Score is 5 as of Jun. 25, 2026. GuruFocus rates MEX:BHCN with a GF Score™ of 48/100 and a GF Value™ of MXN188.23 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Bausch Health ranks better than 94.68% on this metric.

Bausch Health has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Bausch Health has Narrow Moat: Bausch Health benefits from a solid portfolio of patents and a recognizable brand in the healthcare sector. While it has some pricing power and R&D capabilities, it faces significant competition and lacks a dominant market position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bausch Health might have Narrow Moat - Solid narrow moat.

Bausch Health  (MEX:BHCN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bausch Health Moat Score Related Terms

MEX:BHCN vs ZTS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch Health Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Moat Score distribution charts can be found below:

* The bar in red indicates where Bausch Health's Moat Score falls into.


MEX:BHCN
48GF Score
Bausch Health Companies Inc MEX:BHCN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Bausch Health (MEX:BHCN) has a Moat Score of 5 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bausch Health ranks #55 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Bausch Health's Moat Score too high?
Bausch Health's current Moat Score is 5. Based on the distribution chart, Bausch Health ranks #55 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bausch Health has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Moat Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #55 out of 1033 companies for Moat Score. This places Bausch Health in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bausch Health's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (MEX:BHCN) is currently considered Possible Value Trap. The stock's GF Value™ is MXN188.23, compared to a current price of MXN85.44 — trading 54.6% below its estimated fair value. The current Moat Score is 5. Bausch Health's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bausch Health (MEX:BHCN), the current Moat Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (MEX:BHCN) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of MXN85.44 is trading 54.6% below its estimated GF Value™ of MXN188.23. GuruFocus considers Bausch Health to be Possible Value Trap.

Key valuation signals for MEX:BHCN:

  • Moat Score: 5
  • GF Value™: MXN188.23 vs. price of MXN85.44 (54.6% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the MEX:BHCN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
48GF Score

Get the complete analysis for MEX:BHCN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN85.44
Price
MXN188.23
GF Value